Vivani Medical’s, was set to report top-line data later that same week as its November 11 quarterly filing, making this one of the more concrete near-term readouts in the GLP-1 space. The trial enrolled 20 GLP-1-naïve participants in Australia and tested low doses of NPM-139 alongside Wegovy, measuring safety, tolerability, pharmacokinetics, and weight change. What the data show will tell investors whether a once- or twice-yearly implant can deliver semaglutide at meaningful levels, which is the core biological question NPM-139 has to answer before Vivani files an IND for a Phase 2 dose-ranging study planned for 2027.
The implant’s design includes a retrieval option, meaning a clinician can remove it if a patient needs to stop therapy, such as during pregnancy or ahead of surgery with aspiration risk. That feature matters because approved injectable GLP-1 therapies for weight management require patients to simply stop injecting if discontinuation is needed; a subdermal depot without retrieval would carry the same limitation. Vivani notes that more than 20 percent of current GLP-1 users are women of childbearing potential, and a reversible implant addresses a discontinuation scenario that weekly or even monthly injectables cannot replicate. The July 2026 agreement with Novo Nordisk to evaluate NPM-139 carries no exclusivity provisions for NPM-139 or Vivani’s proprietary NanoPortal technology,, so Vivani retains full freedom to partner elsewhere or advance the asset independently.
The company’s other moving part is the Cortigent-ClearOne merger, where Vivani’s neurostimulation subsidiary will become a wholly-owned subsidiary of ClearOne, which will rename itself Cortigent Holdings and trade on Nasdaq under CRGT. Under the merger agreement, MergerSub merges with and into Cortigent, leaving Cortigent as the surviving wholly-owned subsidiary of ClearOne. The deal awaits final regulatory approval, and ClearOne is pursuing concurrent financing of $10 million to $15 million to close alongside it.
Vivani’s cash position dropped from $20.8 million to $15.5 million between June 30 and September 30, with R&D spend of $5.0 million in Q3 driven largely by clinical trial expenses in the Biopharm Division. The SLIM-1 readout is the number to watch: a clean safety profile with detectable pharmacokinetic signal would validate the platform and support the IND submission; anything less reshapes the 2027 timeline.
Source link: https://www.sec.gov/Archives/edgar/data/1266806/000175392626002108/vani-20261111.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
